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Abstract: Necroptosis is a type of regulated cell death that is increasingly being recognized as a
relevant pathway in different pathological conditions. Necroptosis can occur in response to multiple
stimuli, is triggered by the activation of death receptors, and is regulated by receptor-interacting
protein kinases 1 and 3 and mixed-lineage kinase domain-like, which form a regulatory complex called
the necrosome. Accumulating evidence suggests that necroptosis plays a complex role in cancer, which
is likely context-dependent and can vary among different types of neoplasms. Necroptosis serves as
an alternative mode of programmed cell death overcoming apoptosis and, as a pro-inflammatory
death type, it may inhibit tumor progression by releasing damage-associated molecular patterns to
elicit robust cross-priming of anti-tumor CD8+ T cells. The development of therapeutic strategies
triggering necroptosis shows great potential for anti-cancer therapy. In this review, we summarize
the current knowledge on necroptosis and its role in liver biliary neoplasms, underlying the potential
of targeting necroptosis components for cancer treatment.
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1. Introduction
A continuous process of cell death (CD) and renewal takes place on a daily basis in all mammal
organ systems. Disturbances in these processes interrupt the normal regulation of development and
tissue homeostasis with the potential to induce pathological conditions, including cancer [1]. Therefore,
a better understanding of how balance between CD and survival is controlled is highly relevant in
many fields, from developmental alterations to human diseases and cancer research, and may facilitate
the development of novel effective therapies.
Necroptosis is a type of tightly regulated cell death (RCD) mimicking the morphological features
of necrosis [2]. Similar to non-regulated necrosis, it represents an inflammatory mode of CD [2].
Necroptosis and its molecular players contribute to embryonic and post-natal development and
participate in tissue homeostasis [2]. Several studies on cell lines, animal models, and human tissue
have been conducted over the last ten years, demonstrating the involvement of necroptosis in the
pathogenesis and natural course of different pathological conditions. In addition to its key role
in inflammatory conditions, necroptosis seems to be involved in the regulation of cancer biology,
including tumorigenesis, metastasis development, and cancer immunity [3].
A plethora of evidence has shown that a switch from one type of CD to another is possible and
regulated by specific molecules. In particular, the inhibition of caspase-8 shifts extrinsic apoptosis to
a necrosis type of CD, due to the activation of receptor-interacting serine/threonine-protein kinase 3
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(RIPK3) and mixed lineage kinase domain-like (MLKL) [4]. Therefore, necroptosis is an alternative
mode of CD when the caspase-8-dependent apoptotic pathway is blocked. It is now well-established
that various stimuli can initiate necroptosis, including intra- and extracellular factors, such as tumor
necrosis factor α (TNFα) and reactive oxygen species (ROS) [5].
A hallmark of cancer is the ability of malignant cells to evade apoptosis. Therefore, the induction
of necroptosis could be an alternative strategy for killing cancer cells. Several therapeutics able to
affect the necroptotic cascade have recently been developed, and a few of them are already in phase 1
trials for the treatment of inflammatory diseases. Moreover, necroptosis modulation is becoming the
target of several new anti-cancer strategies. In fact, it has been demonstrated that apoptosis-resistant
tumors respond to necroptosis, and that necroptosis can create an immunogenic microenvironment
that enhances tumor clearance [6]. These aspects will be further discussed in the following chapters.
Herein, we will discuss the general aspects of necroptosis and what is currently known on its
involvement in cholangiocarcinoma (CCA), in order to provide perspectives for future studies in this
relatively new field.
2. Overview on Types of Cell Death
In 2005, the Nomenclature Committee on Cell Death (NCCD) defined the first CD classification
purely based on morphological criteria. This classification included three major forms of CD: types
I, II, and III [7]. Type I CD, termed apoptosis, exhibits cell shrinkage, membrane blebbing, DNA
fragmentation, chromatin condensation, and the formation of apoptotic bodies. Apoptosis is a form
of RCD and responds to two different death signals: damage from inside the cell, such as DNA
damage, which elicits an intrinsic pathway, and extracellular stimuli, such as TNFα and the Fas ligand,
which are followed by an extrinsic pathway. Both pathways are well-regulated, take nearly a day
to be effected, and do not involve any neighboring cell or immune cell [8]. Type II CD is known as
autophagy-dependent CD and is also considered to be a form of RCD. It relies on the autophagic
machinery, which usually has cytoprotective effects, leading to cell adaptation to stress (such as
starvation or hypoxia). However, in the case of persistent stress stimuli, autophagy can result in cell
demise. This type of CD is morphologically characterized by extensive cytoplasmic vacuolization and
lysosomal degradation [8,9]. Type III CD, referred to as necrosis, is a consequence of an overwhelming
cytotoxic insult, which cannot be controlled or survived by the cell. Necrosis is generally recognized as
accidental CD and manifests with vacuolation of the cytoplasm, cell swelling, and membrane rupture.
In contrast to apoptosis, necrosis is a fast form of CD, and its presence induces an immunogenic
reaction due to the release of damage-associated molecular patterns (DAMPs), including high-mobility
group box 1 and heat shock protein 70, which act as danger signals alerting the organism about a
potential threat [9–11].
During the last decade, research in this field has taken a big leap forward, resulting in the discovery
of novel triggers and mechanisms of CD. The most studied forms of CD are the three described above,
but it is easy to understand how this classification system, even if still employed, became outdated
and incomplete. For this reason, in 2018, the NCCD published a consensus paper with nomenclature,
definitions, and an updated classification of all currently known forms of CD, centered on a molecular,
biochemical, pharmacological, and functional, rather than morphological, basis, which includes a long
list of all newly recognized forms of CD that has probably not yet reached its full length [9,12–15].
In this new classification, type I CD was definitively split into two different processes, termed intrinsic
and extrinsic apoptosis, while type III CD was renamed mitochondrial permeability transition-driven
necrosis, pointing out the importance acquired by the molecular aspects in defining CD modalities [9].
Moreover, eight new types of CD were identified and well-defined, named necroptosis, ferroptosis,
pyroptosis, parthanatos, entotic CD, NETotic CD, lysosome-dependent CD, and immunogenic CD [9].
It was also clearly specified that molecular mechanisms involved in the initiation and propagation of
different RCD modes exhibit a considerable degree of interconnectivity [9]. Furthermore, different
from what had been reported before, the Committee stated that each type of RCD may manifest with
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an entire spectrum of morphological features ranging from fully necrotic to fully apoptotic, and an
immunomodulatory profile ranging from anti-inflammatory and tolerogenic to pro-inflammatory and
immunogenic [9].
It is now known that a specific microenvironment can elicit specialized forms of CD, some of
which do not take part in normal homeostasis. Subcategories of RCD with a function in physiological
conditions are necroptosis and pyroptosis, which are implicated in development and inflammation.
In contrast, the initiation of other CD-related pathways (ferroptosis, parthanatos, entotic CD, NETotic
CD, lysosome-dependent CD, and autophagy-dependent CD) is restricted to specific pathological
circumstances or toxin exposure [15]. Interplay between these pathways has already been suggested
and should be taken into consideration when exploring possible regulators or biomarkers. For example,
autophagy can induce the machinery of necroptosis, which in turn involves crosstalk with apoptosis
and can even stimulate parthanatos [3]. On the contrary, ferroptosis can inhibit these responses [3].
Indeed, clarifying the links between different types of CD is crucial to understanding, predicting, and
eventually manipulating cell fate, particularly in pathological conditions, such as cancer.
3. Necroptosis
As mentioned above, necroptosis is a recently discovered type of RCD, which, in contrast to
apoptosis, is characterized by morphological features of necrosis [2]. In fact, an increasingly translucent
cytoplasm, the swelling of organelles, lysosomal membrane permeabilization, and an enlarged cell
volume are common features of necroptosis. Nuclei remain intact with mild chromatin condensation,
unlike apoptosis [16]. Necroptosis can be triggered by multiple stimuli that are sensed by specific
receptors. Several intra- and extracellular signals that induce necroptosis have been described.
For instance, intracellular factors such as TNFα, the Fas ligand, the tumor necrosis factor-related
apoptosis-inducing ligand, interferon γ, double-stranded RNA, and adenosine triphosphate (ATP)
depletion, are known to induce necroptosis, as well as extracellular events, such as the production of
ROS, calcium overload, and ischemia/reperfusion injury (IRI) [5,17,18]. All these stimuli act by binding
death receptors, including Fas, TNFα receptor 1 (TNFR1), and pathogen-induced receptors, such as
certain toll-like receptors (TLRs) and Z-DNA binding protein 1 [5,18,19]. Whereas the downstream
cascades activated by TNFR1 have been relatively well-studied, the description of other pathways is
limited to a few models and publications.
TNFα/TNFR1 binding promotes not only necroptosis, but also caspase-dependent apoptosis
and activation of the nuclear factor-kappa B (NF-κB) pathway, which trigger the formation of
pro-inflammatory and pro-survival complexes (Figure 1) [18,19].
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Figure 1. A schematic overview of necroptosis in cholangiocarcinoma (CCA). (a) A simplified 
illustration of the intracellular pathways involved in cell fate in a necroptotic CCA cell. As reported 
in the text, tumor necrosis factor α (TNFα) activates its receptor, TNFα receptor 1 (TNFR1), which 
binds a series of proteins to form complex I. The ubiquitylation of receptor-interacting 
serine/threonine-protein kinase 1 (RIPK1) leads to cell survival, through the nuclear factor-kappa B 
(NF-κB) pathway. When this process is impeded, and caspase-8 is active, complex IIa will assemble, 
leading to RIPK1-independent apoptosis. The deubiquitylation of RIPK1 in the presence of activated 
caspase-8 leads to the assembly of complex IIb and, subsequently, to RIPK1-dependent apoptosis. 
The inhibition of caspase-8 leads to RIPK1/receptor-interacting serine/threonine-protein kinase 3 
(RIPK3)/mixed lineage kinase domain-like (MLKL) interaction, forming complex IIc, also named the 
necrosome. Phosphorylated MLKL and RIPK3 translocate to the plasma membrane, opening 
membrane pores, and resulting in damage-associated molecular patterns (DAMPs) release. (b) The 
immunogenic response to DAMPs. Dendritic cells, activated by DAMPs, travel to lymph nodes, 
mature and expand, and present a tumor antigens to naïve CD8+ T cells, in a process called cross-
priming. T cells are then activated and differentiate into cytotoxic T cells primed to specifically 
attack tumor cells. (c) The morphology of a necroptotic cell. Translucent cytoplasm, the swelling of 
organelles, patches of condensed chromatin within the nucleus, an increased cell volume, and a 
disrupted cell membrane can be visualized by electron microscopy. Picture adopted from 
Vandenabeele et al. [20]. 
TNFR1 activation leads to the formation of the so-called complex I by recruiting TNFR1-
associated death domain (TRADD), TNFR-associated factor 2, RIPK1, the cellular inhibitor of 
apoptosis protein (cIAP) 1-2, and the linear ubiquitin chain assembly complex [18]. Upon the 
formation of complex I, different signaling complexes can follow, which can determine CD or 
Figure 1. A schematic overview of necroptosis in cholangiocarcinoma (CCA). (a) A simplified illustration
of the intracellular pathways involved in cell fate in a necroptotic CCA cell. As reported in the text,
tumor necrosis factor α (TNFα) activates its receptor, TNFα receptor 1 (TNFR1), which binds a series of
proteins to form complex I. The ubiquitylation of receptor-interacting serine/threonine-protein kinase
1 (RIPK1) leads to cell survival, through the nuclear factor-kappa B (NF-κB) pathway. When this
process is impeded, and caspase-8 is active, complex IIa will assemble, leading to RIPK1-independent
apoptosis. The deubiquitylation of RIPK1 in the presence of activated caspase-8 leads to the assembly
of complex IIb and, subsequently, to RIPK1-dependent apoptosis. The inhibition of caspase-8 leads to
RIPK1/receptor-interacting serine/threonine-protein kinase 3 (RIPK3)/mixed lineage kinase domain-like
(MLKL) interaction, forming complex IIc, also named the necrosome. Phosphorylated MLKL and RIPK3
translocate to the plasma membrane, opening membrane pores, and resulting in damage-associated
molecular patterns (DAMPs) release. (b) The immunogenic response to DAMPs. Dendritic cells,
activated by DAMPs, travel to lymph nodes, mature and expand, and present a tumor antigens to
naïve CD8+ T cells, in a process called cross-priming. T cells are then activated and differentiate into
cytotoxic T cells primed to specifically attack tumor cells. (c) The morphology of a necroptotic cell.
Translucent cytoplasm, the swelling of organelles, patches of condensed chromatin within the nucleus,
an increased cell volume, and a disrupted cell membrane can be visualized by electron microscopy.
Picture adopted from Vandenabeele et al. [20].
TNFR1 activation leads to the formation of the so-called complex I by recruiting TNFR1-associated
death domain (TRADD), TNFR-associated factor 2, RIPK1, the cellular inhibitor of apoptosis
protein (cIAP) 1-2, and the linear ubiquitin chain assembly complex [18]. Upon the formation of
complex I, different signaling complexes can follow, which can determine CD or survival [21].
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The polyubiquitination of RIPK1 mediated by cIAP leads to the activation of the pro-survival NF-κB
cascade, which, in turn, mediates the expression of genes encoding for cytoprotective molecules and
stimulates cell survival [22]. However, when NF-κB or its regulators are blocked (for example, by
cIAP inhibition), deubiquitylation of RIPK1 happens, which induces its release and the formation of
other complexes that favor CD. Notably, the deubiquitylation of RIPK1 can also be directly promoted
by drugs, such as the so-called second mitochondrial activator of caspases (Smac) mimetics [23].
The association of Fas-associated protein with the death domain (FADD), TRADD, FLICE-inhibitory
protein (FLIP), and pro-caspase-8 forms cytosolic complex IIa, and the activation of pro-caspase-8
into caspase-8, promotes RIPK1-independent apoptosis [4,18]. However, in the case of knockdown
of the NF-κB essential modulator or blockage of cIAPs or transforming growth factor β-activated
kinase 1 (TAK1), FADD, FLIP, and pro-caspase-8 bind RIPK1 and RIPK3, forming complex IIb, which
is involved in RIPK1-dependent apoptosis [18,19]. On the contrary, when caspase-8 is down-regulated
or inhibited, RIPK1 interacts with RIPK3 and MLKL to form complex IIc, also called the necrosome, by
which necroptosis is initiated [4,18]. Interestingly, it has also been demonstrated in cell lines (e.g., L929
cells and murine embryonic fibroblasts) and murine models (e.g., ethanol-induced liver injury mouse
model) that RIPK3 may also induce necroptosis in the absence of RIPK1, but how RIPK3 might directly
interact with TNFR1 signaling components remains unclear [24]. The ultimate execution step consists
of MLKL phosphorylation by RIPK3, triggering MLKL oligomerization, which is indispensable for
its translocation from the cytosol to the plasma membrane [18,25]. MLKL oligomers mediate plasma
membrane permeabilization, by destabilizing it through a pore-forming complex or by indirectly
inhibiting Ca2+ or Na+ channel functions. This leads to an increase of the intracellular osmotic
pressure and the opening of membrane pores, which represents the last step and one of the hallmarks
of necroptotic CD [9,18]. Bursting of the membrane results in the release of DAMPs, which act as
activators and amplifiers of the inflammatory response. They include molecules which only display
immune activity upon release (i.e., heat shock proteins and extracellular ATP), alarmins, and specific
cytokines, such as different interleukins, which are also able to initiate an inflammatory response [18].
DAMPs are recognized by a series of receptors called “pattern recognition receptors,” such as TLRs
and receptor for advanced glycation end products, which activate the innate immunity and further
evoke the release of cytokines. This, in turn, induces more necrosis and triggers an inflammatory
cascade [4,18]. After the binding of TNFα to its receptor, it takes a few hours until DAMPs are
released [26]. In a neoplastic context, DAMPs attract and activate naïve dendritic cells at the tumor
site, to get rid of tumor antigens. Activated dendritic cells then travel to the lymph nodes, mature and
expand, and finally present tumor antigens to naïve CD8+ T cells. This process, termed cross-priming,
leads to CD8+ T cell activation and differentiation into cytotoxic T cells primed to specifically attack
tumor cells (Figure 1) [27].
Even if the mechanisms involved in the necroptotic cascade are now clearer, the role of necroptosis
in cancer remains complex and difficult to understand. As Gong et al. wrote, necroptosis may be
both a friend and an enemy of cancer [6]. Indeed, the initiation of necroptosis can prevent tumor
development in cells where apoptosis failed. However, at the same time, as a necrotic CD modality,
the inflammatory response that is created after the release of DAMPs promotes angiogenesis, cell
proliferation, and metastasis [6,27–31] (Table 1).
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Table 1. Pro- and anti-tumoral effects of necroptosis.
Pro-Tumoral Effects Anti-Tumoral Effects
Necroptosis results in chronic inflammation and
eventually tumorigenesis [32].
Cross-priming of cytotoxic CD8+ T cells enhances
tumor clearance [33,34].
DAMP-induced inflammation activates the NF-κB
pathway, inhibits apoptosis, and increases genomic
instability [35,36].
RIPK3-induced activation of natural killer T cells
promotes anti-tumor immunity [37].
Necroptosis of endothelial cells and extracellular
matrix induces metastasis [29].
Necroptosis in apoptosis-resistant cancer cells inhibits
carcinogenesis [38,39].
A necroptosis-dominant microenvironment induces
lineage commitment towards intrahepatic CCA [40].
RIPK3 expression levels may predict the efficacy of
cancer immunotherapy [41].
Necroptosis induces the production of molecules that
promote an immune suppressive tumor
microenvironment [30].
The expression of RIPK1, RIPK3, and MLKL, and the double ability of necroptosis of both
promoting and reducing tumor development and growth, have been studied in a variety of tumors,
in order to clarify the relationship with patient prognosis [6]. A reduced expression of key molecules
in the necroptotic pathway has been observed in different cancer cell lines, suggesting that these cells
may evade necroptosis to survive [6]. As a consequence, a lower expression of necroptosis regulators
seems to correlate with a worse prognosis in several types of carcinomas (i.e., breast, colorectal, gastric,
and ovarian cancer, and head and neck and cervical squamous cell carcinoma), in acute myeloid
leukemia, and in melanoma [30,42–48]. However, the expression of RIPK1, RIPK3, and MLKL has
been found to be upregulated in some cancers (i.e., glioblastoma, pancreatic, lung, and esophageal
cancer), in which a high activation of the necroptotic cascade seems to be correlated with a poorer
prognosis in different studies [6,36,41,49–53]. The role of necroptosis in liver carcinogenesis is also
still not clear. In a mouse model of TAK1 deletion in parenchymal liver cells, which induces RCD,
apoptosis, but not necroptosis, promoted carcinogenesis. In these experiments, a pure activation of
necroptosis was related to a suppression in inflammation, proliferation, and carcinogenesis [54,55].
Commonly used human hepatoma cell lines showed a methylation-dependent loss of RIPK3 expression
with a block in the activation of the necroptotic pathway, suggesting that evasion from necroptosis is
an important step in hepatocyte malignant transformation [55]. Furthermore, RIPK3 re-activation by
the demethylation of its promoter can re-sensitize tumor cell lines to chemotherapy, opening a new
approach for hepatocellular carcinoma (HCC) treatment [55]. Altogether, the available data indicate
that the actual effect of necroptosis on cancer varies according to the location, biological features, and
microenvironment of each cancer type [6]. An improved understanding of the mechanisms driving
necroptosis directly implies translational applications. Biomarkers of necroptotic CD might not only
identify patients at risk of cancer development, but also help to delineate tumor prognosis and predict
and monitor the response to treatment [54,55].
4. Overview on Necroptosis in Liver Disease
In healthy conditions, almost all liver cells remain in the G0 phase of the cell cycle, with little
turnover and virtually no CD. In the case of liver injuries of different etiologies, hepatocellular
death occurs, and the liver starts to regenerate in order to preserve its homeostasis and metabolic
functions [54,55]. However, CD in the liver occurs not only as a passive response to insults, but also as
a process actively induced by the host via RCD. As in other organs, it is now evident that in the liver,
besides apoptosis, necroptosis represents a highly relevant form of RCD [54,55]. However, its exact
role in liver biology and pathophysiology is still not well-understood. This is mainly due to the lack of
simple and specific tools for detecting the activation of the necroptotic cascade in vivo [54–56].
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Studies based on immunohistochemistry and Western blot have shown that the expression
of necroptotic markers in hepatocytes is relatively low, suggesting that other cell types, including
cholangiocytes, hepatic stellate cells, Kupffer cells, and endothelial cells, may participate in normal liver
functions, as well as contribute to some forms of liver disease [55,57]. A robust expression of RIPK3
and MLKL has been observed in isolated endothelial and Kupffer cells, and in liver leukocytes [57,58].
RIPK3 is usually expressed at low levels in human hepatocytes and cholangiocytes, whereas an
increased expression can be induced upon caspase-8 deletion and in distinct pathophysiological
conditions, such as drug-induced acute liver injury [16,54,55].
The contribution of necroptosis to liver disease seems to be context-specific and dependent
on the lineage of the involved cells, the etiology, the stage of the disease, and the nature and
extent of co-morbidities [59,60]. Various methods, including pharmacological inhibition and gene
knockout and knockdown, have been utilized to evaluate the role of necroptosis in different
diseases, mostly using murine models [2,54]. As a model of acute liver injury, several groups
focused on acetaminophen-induced hepatic injury (AIHI) in mice, but the results they obtained were
conflicting [2,3,18,57,58,61–68]. Indeed, the involvement of necroptosis in AIHI is still questionable,
and it is still not clear whether RIPK1 or RIPK3 inhibition may have a protective role in this setting [18].
In the setting of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH),
it was initially reported that RIPK3 might maintain white adipose tissue homeostasis and prevent
glucose intolerance by regulating caspase-8 expression, thus reducing adipose tissue apoptosis and
inflammation [2,57,59,69–71]. In a high-fat diet mouse model, RIPK1 inhibition, and the subsequent
downstream necrosome inactivation, improved all the histologic features of NASH, including liver
inflammation and fibrosis [72]. Some studies indicated that the effects of RIPK3 and MLKL blockage
are not consistent, with RIPK3 deletion that seemed to be harmful, while MLKL deletion that seemed to
be beneficial in NAFLD [2,59,69,71]. However, different roles of RIPK3 have been observed in different
mouse models, with some authors reporting an amelioration of liver injury and fibrosis following
RIPK3 inhibition [2,18,55,73,74]. In human NAFLD/NASH biopsy samples and serum, increased
RIPK3 and MLKL expressions have been described, suggesting that necroptosis may also mediate liver
injury, oxidative stress, and liver fibrosis in humans, through a positive feedback loop involving the
activation of Jun N-terminal kinase [2,55,73,75]. Moreover, the serum concentrations of RIPK1 and
MLKL increased with histological activity, and correlated with alanine transaminase (ALT) levels in
patients with NAFLD, suggesting that a blood-based non-invasive assessment of necroptosis activity
could be useful for identifying patients with NASH [72].
In alcoholic liver disease, an increased RIPK3 expression has been observed in human biopsy
samples, as well as in mice after chronic ethanol exposure. RIPK3 ablation can reduce an ethanol-induced
increase in serum ALT, hepatic steatosis, and inflammation [2,54,55,59,76–78].
Controversial data are also available on the role of necroptosis in autoimmune hepatitis
(AIH) [2,18,55,79–82]. A high level of RIPK1 kinase activity and RIPK3 expression has been reported
in murine AIH models and in the liver tissue of AIH patients, respectively [18,37,66,83]. However,
the genetic silencing of RIPK3 in a murine model could not improve AIH [18,66]. Furthermore,
an elevated MLKL expression has been reported in human AIH biopsies and murine models, and it
has been proven that the disease can be driven by an MLKL-dependent pathway, which seems to be
independent of RIPK3 [18,67].
RIPK3 expression has been shown by immunohistochemistry in liver biopsies from patients
with hepatitis B and C virus infections, suggesting that necroptosis may also occur in viral hepatitis;
however, available data on this topic are still very scant [18,84,85].
Different groups have demonstrated the involvement of necroptosis in IRI during orthotopic liver
transplantation, both in murine cell lines and mouse IRI models [18]. In this setting, an increased
expression of necroptosis mediators has been described, and different inhibitors have been used to
block the necroptotic cascade [3,18,55,86–92].
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The activation of the necroptotic pathway has also been described in cholangiopathies [54,93–95].
In mice with bile duct ligation (BDL), caspase inhibitors could only moderately alleviate liver injury,
meaning that apoptosis is not the only type of CD involved in cholestasis and suggesting that, as in
NAFLD/NASH, a switch to necroptosis may occur [18,96]. It has been reported by two different
groups that, in a TAK1-deficient mouse model of cholestasis, hepatocytes die exclusively through
caspase 8-mediated apoptosis, while cholangiocytes can undergo necroptosis, triggered by RIPK1 and
RIPK3 activation [38,39]. The association of necroptosis activation with biliary cell damage and the
development of jaundice suggests that the use of RIPK1 inhibitors could be effective in the treatment
of biliary diseases [18,38,39]. Moreover, it has recently been reported that, in BDL mice, microRNA-21
(miR-21) expression is induced and actively involved in promoting necroptosis. In those experiments,
miR-21 ablation protected against necroptosis, fibrosis, and oxidative stress [2,97]. Finally, although
suggested by only a few studies, it is likely that necroptosis and other types of regulated CD may be
involved in cholangiopathies related to IRI and liver allograft rejection [16].
5. Necroptosis and Cholangiocarcinoma
CCA constitutes a heterogeneous group of liver epithelial malignancies that can develop in any
segment of the biliary tree. It is the second most common primary liver tumor, with an increasing
incidence over the past decades, particularly in Western countries. CCAs exhibit heterogeneous clinical
features, genotypes, and biological behaviors, depending on the anatomical location, growth pattern,
and histological differentiation [98,99]. CCA can be categorized into three different forms, named
intrahepatic, perihilar, and distal CCA, each of which are characterized by their own pathogenesis,
risk factors, and clinical outcome [98,99]. In addition to an increasing incidence, the prognosis of CCA
remains poor, with a median survival of less than 2 years and a survival rate of less than 10%. Due to
the lack of early symptoms and specific biomarkers, CCA diagnosis is frequently reached at advanced
stages, when treatment options are precluded. Surgical resection remains the main potentially curative
treatment, even though this approach can only be performed in about 30% of patients, particularly those
with intrahepatic CCA (iCCA). Unfortunately, the rate of recurrence after resection is still heavy, ranging
from 50% to 60%, and survival at 5 years is less than 45% [100–103]. Another therapeutic option with a
curative intent is represented by orthotopic liver transplantation following neoadjuvant chemotherapy.
This procedure is becoming the standard of care for the treatment of localized iCCA, though it can
only be offered to highly selected patients by a few specialized centers. Moreover, the procedure is
contraindicated by the presence of comorbidities or the neoplastic involvement of regional lymph
nodes. Following liver transplantation, disease-free survival ranges from 23% (for distal CCA) to 65%
(for iCCA and hilar CCA), and thus depends on tumor localization [101–103]. Loco-regional treatments,
such as transarterial chemoembolization or radioembolization, can also be taken into account for
iCCA patients, but the results are limited [103]. Although CCA has been classically regarded as a
highly resistant-to-chemotherapy tumor, little progress has been made over the last years. Combining
gemcitabine and cisplatin has become the standard of care for patients with advanced CCA, showing
an overall survival of 11.7 months, compared to 8.2 months in patients treated with gemcitabine
alone [104]. In addition, several studies and clinical trials have been conducted aiming to tailor the
most effective drug based on genetic signatures of the tumor [103,105]. Based on this, novel approaches
have been devised, such as new small molecules to specifically target mutations or signal pathways
detected in a single patient, or immunotherapy to inhibit one or multiple checkpoints, eventually in
combination with chemotherapy or surgical resection [103,105]. However, data on immunotherapy in
CCA are still limited, even if the anti-PD-1 monoclonal antibody pembrolizumab seems to be promising
in patients with advanced CCA [106]. Mechanisms underpinning chemoresistance in CCA include
escape from drug-induced apoptosis by cancer cells, mediated by autocrine and paracrine cues released
in the tumor microenvironment [107,108]. Therefore, overcoming apoptosis resistance by inducing
necroptosis in cancer cells may provide an attractive tool in the setting of CCA.
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Although research on the role of necroptosis in CCA is at its dawn, a few important first
steps have been made. A recent study on mice addressed how a hepatic microenvironment, created
by two different methods of oncogenic delivery, could influence the type of hepatic tumor [109].
The authors showed that the same oncogenic drivers delivered to mature hepatocytes gave rise to
iCCA when embedded in a necroptosis-dominated microenvironment, while an apoptotic milieu
favored the development of HCC [40,109]. The necroptosis microenvironment was characterized by
specific inflammatory cytokines (e.g., C-C motif ligand 6) secreted from immune cells, which were,
in turn, activated by DAMPs released from necroptotically dying hepatocytes [18,40,59]. Transformed
differentiated hepatocytes that were not surrounded by a necroptotic microenvironment gave rise to
HCC or combined iCCA-HCC. Notably, transformed cholangiocytes could only degenerate into CCA
and not HCC [40,109]. Further analysis found no role for stellate cells, immune cells, or overall death in
modulating the hepatic microenvironment, which also seems to be independent of the oncogenic driver
used [40,109]. Moreover, in the necroptotic microenvironment, the administration of necrostatin-1
(Nec-1) not only inhibited necroptosis, but also reduced cytokine release and shifted death from
necroptosis to apoptosis, switching iCCA to HCC development [40,109]. Similar results were observed
in hepatocyte-specific MLKL-KO mice [40,109]. Of note, the shift in tumor type occurred during
the tumorigenesis phase, and not when the tumor was already developed [40,109]. The underlying
molecular mechanisms that determine the preference of hepatocytes for apoptosis or necroptosis are
still largely unknown, and whether or not the type of CD could also influence the tumor type in
human chronic liver diseases has not yet been clarified [40,109]. In summary, Seehawer et al. provided
an innovative insight into how the tumor microenvironment can be shaped by a specific CD type,
eventually regulating lineage commitment in liver tumorigenesis [40]. These findings suggest that,
during chronic liver diseases, a shift towards less fatal conditions with an improved prognosis could
be possible, thus changing the natural course of disease progression [40,109].
Very few literature data regarding the prognostic role of necroptosis markers in CCA are currently
available. Our group investigated this topic for the first time, in a series of 61 well-characterized and
selected small and large bile duct iCCAs, by using immunostaining for RIPK3, RIPK1, and pMLKL.
We found that all of these necroptosis-related proteins were highly expressed in the majority of cases,
implying the presence and activation of the necroptotic cascade in iCCA. Moreover, their expression
was found to be inversely correlated with the presence of iCCA negative prognostic factors, such
as perineural invasion and nodal metastasis. Notably, we observed a significantly increased overall
survival in patients with higher RIPK3 and RIPK1 expression. Furthermore, we described a direct
relationship between RIPK3 expression and the number of intratumoral CD8+ T cells (only abstract
available [110]). Therefore, overall, our preliminary data suggest a favorable role of necroptosis
in iCCA.
6. Necroptosis-Based Therapies for Cholangiocarcinoma
Over the last years, several medications have been developed to modulate necroptosis, and
numerous studies have provided the basis for moving some of these therapies toward clinical
settings [2,18,31,54,55,59,72,111,112]. From what has been reported above, it is clear that RIPK1 and
RIPK3 functions are essential for necroptotic cascade initiation and that it is possible to regulate
necroptosis by acting on the functions of these molecules [4]. For example, Nec-1 is a well-investigated
inhibitor of necroptosis that targets the catalytic and allosteric functions of RIPK1, thus preventing
formation of the necrosome. Caspase-8 is able to block necroptosis by cleaving RIPK1 and RIPK3,
and its activity can be modulated, both pharmaceutically and genetically (e.g., by deletion), to favor
necroptosis [113]. At present, one of these drugs, an RIPK1 inhibitor, is in a phase 1 human clinical trial
for the treatment of amyotrophic lateral sclerosis [112]. Moreover, some RIPK1 and RIPK3 inhibitors
will likely be tested for chronic liver diseases very soon [59]. In the cancer setting, over the last few years,
several methods have been studied to induce necroptosis as a putative therapeutic agent: radiotherapy,
classical chemotherapeutic agents (such as 5-fluorouracil), kinase inhibitors (such as dorsomorphin),
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death receptor ligands (such as the CD95 ligand), oncolytic viruses, metal nanoparticles, Smac mimetics
(RIPK1 activators), proteasome inhibitors, obatoclax (an inhibitor of anti-apoptotic Bcl-2 proteins),
and polyinosinic:polycytidylic acid (PolyI:C; a TLR3 agonist) [6]. Combining necroptosis-inducing
strategies with anti-apoptosis drugs allows apoptosis resistance to be easily bypassed. For instance,
PolyI:C in combination with zVAD (a pan-caspase inhibitor) resulted in necroptotic CD in colon cancer,
both in vivo and in vitro [33]. Concordantly, Smac mimetics combined with caspase-8 inhibitors have
been shown to be effective in human acute myeloid leukemia cells and ovarian cancer cell lines and
xenografts [114,115]. This suggests that inducing necroptosis could be used as a second-line treatment
in cancer patients after the development of resistance to apoptosis [116–118]. Natural compounds
such as shikonin (a component of a Chinese herbal medicine), staurosporine (an alkaloid extracted
from the bacterium Streptomyces staurosporeus), neoalbaconol (a compound of a fungus), and bufalin
(an ingredient of a Chinese medicine isolated from the skin and glands of toads) were also able to
trigger necroptosis, with anti-tumoral outcomes [6,119–121]. Recent results of some clinical studies
confirmed that necroptosis promotes natural or therapy-driven anti-cancer immunosurveillance in
different neoplasms, including breast and ovarian carcinoma [3].
A widely adopted approach for killing cancer cells is to activate apoptosis, and evasion from this
type of CD is considered a key step to therapeutic failure and chemotherapy resistance in CCA [122],
as reported above. A switch to a non-apoptotic CD, such as necroptosis, can function as a backup system
in apoptosis-resistant cells, so antitumor drugs inducing non-apoptotic CD are now considered a new
approach for overcoming such a big obstacle in CCA treatment [0]. Only two studies have investigated
the efficacy of different drugs in limiting CCA development by inducing necroptosis in CCA cell lines.
Akara-amornthum et al. demonstrated that treatment with both TNFα and a Smac mimetic induced
RIPK1/RIPK3/MLKL-dependent necroptosis when caspase was blocked, evidenced by an increased
expression of RIPK3 and MLKL in CCA cell lines after treatment [122]. They also proved that the
administration of a Smac mimetic could sensitize CCA cells to a low dose of standard chemotherapy
with gemcitabine, by increasing TNFα mRNA levels and reversing gemcitabine-induced cell cycle
arrest, leading to CD [122]. Xu et al. reported, for the first time, that matrine, an alkaloid isolated
from traditional Chinese medicine Sophora flavescens, induced necroptosis in CCA cell lines, differing
from its classical role of inducing apoptosis in many other types of cancer cells [123]. The authors
showed that CCA cells under matrine treatment exhibited a typical necrosis-like morphology instead
of apoptotic changes, and that these effects were greatly attenuated by Nec-1, but not by the apoptosis
inhibitor zVAD [123]. A moderate expression of RIPK3 was observed in CCA cells and was required
for matrine to induce necroptosis, which switched to apoptosis after endogenous R.
IPK3 knock down. Moreover, MLKL translocation from the cytoplasm to plasma membrane,
as well as the increased production of ROS by RIPK3/MLKL, were critical for matrine to induce
necroptosis. The authors also described a moderate increase in RIPK3 expression in most tissue samples
from CCA patients, compared with adjacent normal tissues [0].
Overall, targeting necroptosis holds great promise for anti-cancer therapies, particularly in CCA
patients, and ongoing efforts are focused on developing specific and stable pharmaceutical combinations.
7. Conclusions
CCA is an aggressive tumor with several clinical gaps that need to be filled. With limited treatment
options at diagnosis, its management remains challenging. Therefore, it is crucial to develop effective
therapeutic agents able to reduce the mortality of CCA patients.
Molecular insights into necroptosis mechanisms and their relevance in the pathobiology of
liver diseases have been increased substantially over the last period. The necrosome components
MLKL, RIPK1, and RIPK3, are critical regulators of necroptotic CD, with MLKL functioning as the
executioner of necroptosis. Modulating necroptosis by regulating necrosome components might
provide an interesting therapeutic tool.
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Data on the role of necroptosis in CCA are scant but promising. Importantly, several questions
need to be addressed in future research: What signal(s) triggers necroptosis in CCA cells during tumor
development? Is the evasion of necroptosis a critical event for CCA development and progression?
What are the regulatory mechanisms of necroptosis in CCA? An additional characterization of
necroptosis, using specific biomarkers in human pathological samples, will be critical to unveiling the
significance of necroptosis in CCA.
As new studies clarifying the mechanisms and the role of necroptosis in CCA are eagerly awaited
in the near future, we believe that different therapeutic approaches should be explored and may
hopefully result in innovative and effective treatments for CCA.
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AIH autoimmune hepatitis
AIHI acetaminophen-induced hepatic injury
ALT alanine transaminase
ATP adenosine triphosphate
BDL bile duct ligation
CCA cholangiocarcinoma
CD cell death
cIAP cellular inhibitor of apoptosis protein
DAMPs damage-associated molecular patterns






MLKL mixed lineage kinase domain-like
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NCCD Nomenclature Committee on Cell Death
Nec-1 necrostatin-1
NF-κB nuclear factor-kappa B
PolyI:C polyinosinic:polycytidylic acid
RCD regulated cell death
RIPK3 receptor-interacting serine/threonine-protein kinase 3
ROS reactive oxygen species
Smac second mitochondrial activator of caspases
TAK1 transforming growth factor β-activated kinase 1
TLRs toll-like receptors
TNFα tumor necrosis factor α
TNFR1 TNFα receptor 1
TRADD TNFR1-associated death domain
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